Q1 2026 · 13F-HR
Sofinnova Investments, Inc.holdings as filed
Filed 2026-05-15 · accession 0001104659-26-062256
$2.63B
Reported value
74
Positions
2026-03-31
Period end
The Brief · Sofinnova Investments, Inc. · Q1 2026
AI · grounded in 13F
Sofinnova Investments, Inc. closed its position in AZNN for a reduction of $150.1M. The fund established several new positions, led by a $148.8M investment in IWM and $134.1M in XBI. Other notable activity includes new stakes in AZN for $89.9M and QQQ for $86.6M, alongside the closure of positions in VRTX and ABBV.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 632307104 | NTRA | Natera Inc | $310.0M | 11.8% | 1,550,280 | Common | SOLE |
| 464287655 | IWM | iShares TR | $148.8M | 5.66% | 600,000 | PUT | SOLE |
| 78464A870 | XBI | SPDR Series Trust | $134.1M | 5.10% | 1,050,000 | PUT | SOLE |
| 110122108 | BMY | Bristol-Myers Squibb Co | $120.6M | 4.58% | 1,988,721 | Common | SOLE |
| G50871105 | JAZZ | Jazz Pharmaceuticals PLC | $113.1M | 4.30% | 598,327 | Common | SOLE |
| 92337R101 | VERA | Vera Therapeutics Inc | $112.4M | 4.27% | 2,793,987 | Common | SOLE |
| 91307C102 | UTHR | United Therapeutics Corp | $94.9M | 3.61% | 160,070 | Common | SOLE |
| G0593M107 | AZN | AstraZeneca PLC | $89.9M | 3.42% | 456,031 | Common | SOLE |
| 46090E103 | QQQ | Invesco QQQ TR | $86.6M | 3.29% | 150,000 | PUT | SOLE |
| 19240Q201 | COGT | Cogent Biosciences Inc | $81.4M | 3.09% | 2,113,551 | Common | SOLE |
| 464287556 | IBB | iShares TR | $80.2M | 3.05% | 475,000 | PUT | SOLE |
| 90400D108 | RARE | Ultragenyx Pharmaceutical Inc | $65.9M | 2.50% | 3,145,888 | Common | SOLE |
| 75383L102 | RAPP | Rapport Therapeutics Inc | $59.6M | 2.26% | 1,904,408 | Common | SOLE |
| 457669307 | INSM | Insmed Inc | $56.6M | 2.15% | 346,075 | Common | SOLE |
| H01301128 | ALC | Alcon AG | $55.0M | 2.09% | 729,972 | Common | SOLE |
| 868459108 | SUPN | Supernus Pharmaceuticals | $49.3M | 1.87% | 954,309 | Common | SOLE |
| 91307C102 | UTHR | United Therapeutics Corp | $47.6M | 1.81% | 80,300 | PUT | SOLE |
| 09061G101 | BMRN | BioMarin Pharmaceutical Inc | $44.2M | 1.68% | 781,982 | Common | SOLE |
| 09062X103 | BIIB | Biogen Inc | $42.1M | 1.60% | 229,521 | Common | SOLE |
| 15102K100 | CELC | Celcuity Inc | $41.8M | 1.59% | 366,175 | Common | SOLE |
| 09077V100 | BIOA | BioAge Labs Inc | $40.1M | 1.52% | 2,293,788 | Common | SOLE |
| 76243J105 | RYTM | Rhythm Pharmaceuticals Inc | $39.1M | 1.49% | 450,096 | Common | SOLE |
| 04272N102 | AVBP | Arrivent BioPharma Inc | $39.1M | 1.49% | 1,696,752 | Common | SOLE |
| 45166A102 | IDYA | IDEAYA Biosciences Inc | $37.7M | 1.43% | 1,131,786 | Common | SOLE |
| 45257U108 | IMNM | Immunome Inc | $37.2M | 1.41% | 1,701,904 | Common | SOLE |
| 640268306 | NKTR | Nektar Therapeutics | $36.7M | 1.39% | 509,546 | Common | SOLE |
| 05464T104 | AXSM | Axsome Therapeutics Inc. | $36.0M | 1.37% | 212,747 | Common | SOLE |
| N44445109 | IMTX | Immatics N.V | $35.7M | 1.36% | 3,630,454 | Common | SOLE |
| 15102K100 | CELC | Celcuity Inc | $34.2M | 1.30% | 300,000 | PUT | SOLE |
| 05464T104 | AXSM | Axsome Therapeutics Inc. | $33.8M | 1.28% | 200,000 | PUT | SOLE |
| 10806X102 | BBIO | BridgeBio Pharma Inc | $30.4M | 1.15% | 409,183 | Common | SOLE |
| 26818M108 | DYN | Dyne Therapeutics Inc | $29.6M | 1.13% | 1,633,897 | Common | SOLE |
| 45720N103 | INBX | Inhibrx Biosciences Inc | $27.3M | 1.04% | 406,029 | Common | SOLE |
| 252131107 | DXCM | Dexcom Inc | $24.7M | 0.94% | 393,576 | Common | SOLE |
| N69605108 | PHVS | Pharvaris N V | $23.1M | 0.88% | 818,328 | Common | SOLE |
| 717081103 | PFE | Pfizer Inc | $22.5M | 0.85% | 800,000 | CALL | SOLE |
| 74006W207 | PRAX | Praxis Precision Medicines Inc | $20.5M | 0.78% | 63,680 | Common | SOLE |
| 372303206 | GMAB | Genmab A/S | $20.2M | 0.77% | 752,261 | Common | SOLE |
| 03969F109 | RCUS | Arcus Biosciences Inc | $19.9M | 0.76% | 923,086 | Common | SOLE |
| 53635D202 | LQDA | Liquidia Corporation | $18.9M | 0.72% | 500,000 | PUT | SOLE |
| 98420N105 | XENE | Xenon Pharmaceuticals Inc | $17.7M | 0.67% | 305,216 | Common | SOLE |
| 863667101 | SYK | Stryker Corporation | $14.6M | 0.56% | 44,480 | Common | SOLE |
| 032724106 | ANAB | AnaptysBio Inc | $13.8M | 0.52% | 248,253 | Common | SOLE |
| G76279101 | ROIV | Roivant Sciences Ltd | $13.2M | 0.50% | 477,995 | Common | SOLE |
| 28036F105 | EWTX | Edgewise Therapeutics Inc | $12.2M | 0.46% | 386,498 | Common | SOLE |
| 20454B104 | CMPX | Compass Therapeutics Inc | $10.9M | 0.41% | 2,056,161 | Common | SOLE |
| 30161Q104 | EXEL | Exelixis Inc | $10.8M | 0.41% | 251,500 | PUT | SOLE |
| 68622P109 | ORIC | Oric Pharmaceuticals Inc | $8.6M | 0.33% | 679,578 | Common | SOLE |
| 87583X109 | TNGX | Tango Therapeutics Inc | $8.3M | 0.31% | 395,081 | Common | SOLE |
| 90240B106 | TYRA | Tyra Biosciences Inc | $7.8M | 0.30% | 204,015 | Common | SOLE |
| 76029N106 | REPL | Replimune Group Inc | $7.8M | 0.30% | 1,015,400 | CALL | SOLE |
| 90400D108 | RARE | Ultragenyx Pharmaceutical Inc | $7.3M | 0.28% | 350,000 | CALL | SOLE |
| 05463X106 | AXGN | AxoGen Inc | $7.0M | 0.27% | 210,665 | Common | SOLE |
| 24477V105 | DFTX | Definium Therapeutics Inc | $6.5M | 0.25% | 344,166 | Common | SOLE |
| 23282W605 | CYTK | Cytokinetics Inc | $6.0M | 0.23% | 91,791 | Common | SOLE |
| 254604101 | IRON | Disc Medicine Inc | $5.0M | 0.19% | 78,320 | Common | SOLE |
| 922967104 | MANE | Veradermics Inc | $4.6M | 0.18% | 73,315 | Common | SOLE |
| 413197104 | HRMY | Harmony Biosciences Hldgs Inc | $4.3M | 0.16% | 152,695 | Common | SOLE |
| 92243G108 | PCVX | Vaxcyte Inc | $2.9M | 0.11% | 50,600 | Common | SOLE |
| 20454B104 | CMPX | Compass Therapeutics Inc | $2.6M | 0.10% | 500,000 | CALL | SOLE |
| 604749101 | MIRM | Mirum Pharmaceuticals Inc | $2.5M | 0.10% | 27,591 | Common | SOLE |
| 65343E207 | NXTC | Nextcure Inc | $2.4M | 0.09% | 222,654 | Common | SOLE |
| 805111101 | SVRA | Savara Inc | $2.0M | 0.08% | 364,763 | Common | SOLE |
| G31249108 | ESTA | Establishment Labs Hldgs Inc | $1.9M | 0.07% | 33,930 | Common | SOLE |
| 004225108 | ACAD | Acadia Pharmaceuticals Inc | $1.7M | 0.07% | 78,551 | Common | SOLE |
| 88032L605 | TENX | Tenax Therapeutics Inc | $1.7M | 0.06% | 104,400 | Common | SOLE |
| 008064206 | JBIO | Jade Biosciences Inc | $1.5M | 0.06% | 107,391 | Common | SOLE |
| Y95308105 | WVE | Wave Life Sciences Ltd | $1.4M | 0.05% | 189,253 | Common | SOLE |
| 81734D104 | SEPN | Septerna Inc | $1.1M | 0.04% | 47,506 | Common | SOLE |
| 68277Q105 | OKUR | Onkure Therapeutics Inc | $586,638 | 0.02% | 141,700 | Common | SOLE |
| 097702203 | BOLT | Bolt Biotherapeutics Inc | $556,393 | 0.02% | 137,721 | Common | SOLE |
| 834203309 | SLNO | Soleno Therapeutics Inc | $491,788 | 0.02% | 14,689 | Common | SOLE |
| 45175G207 | IMA | ImageneBio Inc | $159,420 | 0.01% | 31,884 | Common | SOLE |
| 98985Y108 | ZYME | Zymeworks Inc | $40,314 | 0.00% | 1,610 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.